{"analyses":[{"ciLowerLimit":"0.38","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.67","estimateComment":"Hazard ratio and its CI were estimated from Cox proportional hazard model adjusting for the stratification factors noted above.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.51","statisticalComment":"Stratified by 3 factors: previous rituximab treatment, time since last antilymphoma therapy (≤ 2, \\> 2 years), and disease histology (FL, MZL).","statisticalMethod":"Stratified Log-Rank Test"}],"classes":[{"categories":[{"measurements":[{"comment":"Not enough events had occurred at the time of the data cut-off date","groupId":"OG000","lowerLimit":"22.1","upperLimit":"NA","value":"27.6"},{"groupId":"OG001","lowerLimit":"11.4","upperLimit":"16.7","value":"13.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"description":"Event-free survival (EFS) was defined as the time from date of randomization to date of first documented progression, relapse, institution of new anti-lymphoma treatment (chemotherapy, radiotherapy or immunotherapy) or death from any cause. Responding participants and those who were lost to follow up were censored at their last tumor assessment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received rituximab 375 mg/m\\^2 intravenously (IV) every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from Cycles 2 to 5 plus lenalidomide 20 mg by mouth (PO) once daily on Days 1 to 21 every 28 days up to 12 cycles (21-day treatment and 7-day rest period); if creatinine clearance (CrCl) was ≥ 30 mL/min but \\< 60 mL/min, participants received lenalidomide 10 mg capsules on days 1 to 21 every 28 days.","id":"OG000","title":"Rituximab + Lenalidomide (R^2)"},{"description":"Participants received rituximab 375 mg/m\\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from cycle 2 to 5 plus placebo (identically matched capsule) once daily on Days 1 to 21 of every 28-day cycle up to 12 cycles.","id":"OG001","title":"Rituximab + Placebo"}],"paramType":"MEDIAN","populationDescription":"The ITT population was defined as all participants who were randomized into the trial, regardless of whether they received study treatment or not.","reportingStatus":"POSTED","timeFrame":"From date of randomization to data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).","title":"Kaplan Meier Estimate of Event Free Survival as Assessed by the IRC According to the 2007 IWGRC","type":"SECONDARY","unitOfMeasure":"months"}